Lilly allocates $1.42 billion for Zyprexa settlement

10/21/2008 | Wall Street Journal, The

Eli Lilly and Co. said it expects to pay $1.42 billion to settle litigation with the U.S. Attorney's Office in Philadelphia involving claims that the company downplayed the adverse effects of Zyprexa when it promoted the psychiatric drug for off-label use. Lilly said it is in advanced talks with prosecutors and is willing to "intensify efforts to resolve these issues."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA